Total Payments
$529,658
2024 Payments
$121,506
Companies
20
Transactions
350
Medicare Patients
1,270
Medicare Billing
$139,910
Payment Breakdown by Category
Consulting$234,762 (44.3%)
Research$165,151 (31.2%)
Other$74,215 (14.0%)
Travel$44,955 (8.5%)
Food & Beverage$8,663 (1.6%)
Education$1,912 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $234,762 | 77 | 44.3% |
| Unspecified | $165,151 | 70 | 31.2% |
| Honoraria | $46,098 | 14 | 8.7% |
| Travel and Lodging | $44,955 | 63 | 8.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,368 | 4 | 3.5% |
| Food and Beverage | $8,663 | 115 | 1.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $6,750 | 1 | 1.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,000 | 1 | 0.6% |
| Education | $1,912 | 5 | 0.4% |
Payments by Type
General
$364,507
280 transactions
Research
$165,151
70 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $131,030 | 110 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $124,484 | 93 | $0 (2024) |
| Eli Lilly and Company | $84,418 | 23 | $0 (2024) |
| Kowa Pharmaceuticals America, Inc. | $51,864 | 43 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $47,900 | 17 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $29,477 | 10 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $20,474 | 21 | $0 (2024) |
| Mylan Inc. | $15,255 | 12 | $0 (2024) |
| PFIZER INC. | $11,949 | 6 | $0 (2017) |
| Intercept Pharmaceuticals, Inc. | $6,750 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $121,506 | 42 | Eli Lilly and Company ($68,720) |
| 2023 | $38,206 | 56 | Regeneron Pharmaceuticals, Inc. ($13,027) |
| 2022 | $24,859 | 33 | Regeneron Pharmaceuticals, Inc. ($17,730) |
| 2021 | $14,659 | 20 | Regeneron Pharmaceuticals, Inc. ($11,655) |
| 2020 | $81,930 | 43 | Regeneron Pharmaceuticals, Inc. ($54,687) |
| 2019 | $78,889 | 47 | Amgen Inc. ($49,068) |
| 2018 | $43,423 | 35 | AstraZeneca Pharmaceuticals LP ($14,650) |
| 2017 | $126,186 | 74 | Amgen Inc. ($32,177) |
All Payment Transactions
350 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $8,294.00 | General |
| 12/04/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 11/16/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 11/16/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $338.33 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $226.86 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $202.21 | General |
| 10/15/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/08/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $2,262.00 | General |
| 10/01/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | — | Cash or cash equivalent | $445.63 | Research |
| Study: Research Publication/ Writing Support • Category: Cardiology/Vascular Diseases | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $66,838.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 08/31/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $54.04 | General |
| 08/26/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,750.00 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/06/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $638.88 | General |
| 08/02/2024 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $375.68 | Research |
| Study: AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 07/02/2024 | Amgen Inc. | — | Travel and Lodging | Cash or cash equivalent | $443.99 | General |
| 07/02/2024 | Amgen Inc. | — | Travel and Lodging | Cash or cash equivalent | $246.03 | General |
| 07/02/2024 | Amgen Inc. | — | Food and Beverage | Cash or cash equivalent | $21.44 | General |
| 06/10/2024 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $1,051.21 | Research |
| Study: AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 06/06/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $8,671.00 | General |
| 06/06/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $3,770.00 | General |
| 05/17/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $24.96 | General |
| 05/17/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $21.36 | General |
| 05/17/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $4.96 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $66,838 | 1 |
| Evinacumb Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $54,317 | 16 |
| PRALUENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $12,119 | 10 |
| A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SAFETY AND EFFICACY, FOLLOWING REPEAT-DOSE ADMINISTRATION OF EVINACUMAB (ANTI-ANGPTL3) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG) AT RISK FOR ACUTE PANCREATITIS | Regeneron Pharmaceuticals, Inc. | $7,201 | 12 |
| GOULD | Amgen Inc. | $7,049 | 3 |
| Research Medical Writing and Publication Support | Novartis Pharmaceuticals Corporation | $5,421 | 1 |
| AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | Regeneron Pharmaceuticals, Inc. | $4,457 | 11 |
| HEALTH ECONOMICS OUTCOME RESEARCH RELATED TO PRALUENT | Regeneron Pharmaceuticals, Inc. | $2,978 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | Regeneron Pharmaceuticals, Inc. | $1,381 | 1 |
| EVINACUMB CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $844.62 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF VARYING DOSES AND DOSE REGIMENS OF EVINACUMAB IN PATIENTS WITH PERSISTENT HYPERCHOLESTEROLEMIA DESPITE MAXIMALLY TOLERATED LIPID MODIFYING THERAPY | Regeneron Pharmaceuticals, Inc. | $818.98 | 2 |
| A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | Regeneron Pharmaceuticals, Inc. | $467.19 | 1 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $445.63 | 1 |
| Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia | Amgen Inc. | $299.80 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUSFAMILIAL HYPERCHOLESTEROLEMIA | Regeneron Pharmaceuticals, Inc. | $210.02 | 1 |
| Primary 2-Year Results of GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Diseas | Amgen Inc. | $157.77 | 1 |
| (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States | Amgen Inc. | $73.33 | 1 |
| Use of guideline-recommended risk-reduction strategies among patients with Type 2 diabetes and estab | Amgen Inc. | $71.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 355 | 541 | $159,750 | $40,974 |
| 2022 | 3 | 298 | 446 | $141,120 | $37,101 |
| 2021 | 4 | 309 | 458 | $134,510 | $35,158 |
| 2020 | 5 | 308 | 456 | $129,770 | $26,677 |
Total Patients
1,270
Total Services
1,901
Medicare Billing
$139,910
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 184 | 329 | $101,990 | $26,575 | 26.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 72 | 98 | $43,120 | $11,561 | 26.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 21 | 21 | $10,920 | $2,201 | 20.2% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 78 | 93 | $3,720 | $637.71 | 17.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 148 | 243 | $75,330 | $20,426 | 27.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 79 | 112 | $49,280 | $13,650 | 27.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 25 | 33 | $14,190 | $2,601 | 18.3% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 46 | 58 | $2,320 | $424.58 | 18.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 155 | 282 | $87,420 | $24,325 | 27.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 33 | 36 | $15,840 | $4,617 | 29.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 35 | $15,050 | $2,959 | 19.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 25 | 25 | $13,000 | $2,707 | 20.8% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 69 | 80 | $3,200 | $550.01 | 17.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 145 | 271 | $84,010 | $18,231 | 21.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 40 | 48 | $20,640 | $3,439 | 16.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 19 | 19 | $9,880 | $2,030 | 20.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 12 | 14 | $6,160 | $1,343 | 21.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 12 | 12 | $3,480 | $577.66 | 16.6% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 68 | 80 | $3,200 | $573.98 | 17.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 12 | 12 | $2,400 | $482.03 | 20.1% |
About Dr. Robert Rosenson, MD
Dr. Robert Rosenson, MD is a Cardiovascular Disease healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760407449.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Rosenson, MD has received a total of $529,658 in payments from pharmaceutical and medical device companies, with $121,506 received in 2024. These payments were reported across 350 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($234,762).
As a Medicare-enrolled provider, Rosenson has provided services to 1,270 Medicare beneficiaries, totaling 1,901 services with total Medicare billing of $139,910. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location New York, NY
- Active Since 07/13/2006
- Last Updated 12/05/2023
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1760407449
Products in Payments
- Repatha (Biological) $92,224
- EPANOVA (Drug) $47,928
- EVKEEZA (Biological) $40,799
- PRALUENT ALIROCUMAB INJECTION (Biological) $22,027
- PRALUENT (Drug) $21,880
- LIPITOR (Drug) $11,840
- NO PRODUCT DISCUSSED (Drug) $7,598
- LEQVIO (Drug) $7,505
- PELACARSEN (Drug) $7,200
- PRALUENT (Biological) $7,193
- OCALIVA (Drug) $6,750
- JUXTAPID (Drug) $2,322
- Livalo (Drug) $2,290
- Vascepa (Drug) $59.25
- NEXLETOL (Drug) $33.80
- ZIO XT Patch (Device) $18.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in New York
Dr. Roger Hajjar, Md, MD
Cardiovascular Disease — Payments: $5.2M
Cardiovascular Disease $5.2M
Dr. Jacob Koruth, M.d, M.D
Cardiovascular Disease — Payments: $3.2M
Cardiovascular Disease $3.2M
Dr. Martin Leon, M.d, M.D
Cardiovascular Disease — Payments: $2.7M
Cardiovascular Disease $2.7M
Dr. Gregg Stone, M.d, M.D
Cardiovascular Disease — Payments: $2.2M
Cardiovascular Disease $2.2M
Adam Rosenbluth, Md, MD
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Dr. Deepak Bhatt, Md, MD
Cardiovascular Disease — Payments: $1.4M
Cardiovascular Disease $1.4M